Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction, 91757 [2024-27082]

Download as PDF 91757 Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices ACF is currently working on future revisions to this information collection, which will be submitted to OMB for review and approval in 2025. Notices inviting public comment on those revisions will accompany that request, but comments received in response to this notice could also inform those revisions. Through this request process minor discrepancies were noted between the OMB-approved instruments and those currently in use. These minor errors were fixed in the versions included with the request to OMB. Respondents: General Departmental (GDSRAE), State (SSRAE), and Competitive (CSRAE) grant recipients, their subrecipients, and program participants. ANNUAL BURDEN ESTIMATES Number of respondents (total over request period) Instrument Number of responses per respondent (total over request period) Avg. burden per response (in hours) Total/ annual burden (in hours) (1) Participant Entry Survey GDSRAE participants ...................................................................................... SSRAE participants ......................................................................................... CSRAE participants ......................................................................................... 126,130 317,633 20,136 1 1 1 0.1333 0.1333 0.1333 16,813 42,340 2,684 1 1 1 0.1667 0.1667 0.1667 16,821 42,360 2,685 2 2 2 16 16 16 3,808 1,248 1,088 2 2 2 13 13 13 6,552 11,076 1,638 (2) Participant Exit Survey GDSRAE participants ...................................................................................... SSRAE participants ......................................................................................... CSRAE participants ......................................................................................... 100,904 254,106 16,109 (3) Performance reporting data entry form: grant recipients GDSRAE grant recipients ................................................................................ SSRAE grant recipients ................................................................................... CSRAE grant recipients ................................................................................... 119 39 34 (4) Performance reporting data entry form: subrecipients GDSRAE subrecipients ................................................................................... SSRAE subrecipients ...................................................................................... CSRAE subrecipients ...................................................................................... Estimated Total Annual Burden Hours: 149,113. Authority: 42 U.S.C. 1310. Mary C. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2024–27053 Filed 11–19–24; 8:45 am] BILLING CODE 4184–83–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2024–P–4163] khammond on DSK9W7S144PROD with NOTICES Determination That NOXAFIL (Posaconazole) Delayed-Release Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on October 16, 2024. The SUMMARY: VerDate Sep<11>2014 18:39 Nov 19, 2024 Jkt 265001 252 426 63 document announced that NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g), was not withdrawn from sale for reasons of safety or effectiveness. The document incorrectly listed the dosage strength as 100 g. The correct strength is 100 milligrams (mg). This notice corrects that error. FOR FURTHER INFORMATION CONTACT: Awo Archampong-Gray, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6243, Silver Spring, MD 20993–0002, 301– 796–0110, Awo.Archampong-Gray@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: In FR Doc. 2024–23811, published in the Federal Register of Wednesday, October 16, 2024 (89 FR 83504), appearing on pages 83504 and 83505, the following corrections are made: 1. On page 83504, in the second column, the title of the document is corrected to read ‘‘Determination That NOXAFIL (Posaconazole) DelayedRelease Tablets, 100 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness.’’ PO 00000 Frm 00086 Fmt 4703 Sfmt 9990 2. On page 83504, in the third column, in the SUMMARY, in the first paragraph, ‘‘NOXAFIL (posaconazole) delayed-release tablets, 100 grams (g),’’ is corrected to read ‘‘NOXAFIL (posaconazole) delayed-release tablets, 100 milligrams (mg),’’. 3. On page 83505, in the first and second columns, all uses of ‘‘100 g’’ are corrected to read ‘‘100 mg’’. Dated: November 7, 2024. Kimberlee Trzeciak, Deputy Commissioner for Policy, Legislation, and International Affairs. [FR Doc. 2024–27082 Filed 11–19–24; 8:45 am] BILLING CODE 4164–01–P E:\FR\FM\20NON1.SGM 20NON1

Agencies

[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Page 91757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27082]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-P-4163]


Determination That NOXAFIL (Posaconazole) Delayed-Release 
Tablets, 100 Grams Was Not Withdrawn From Sale for Reasons of Safety or 
Effectiveness; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register on October 16, 2024. The document 
announced that NOXAFIL (posaconazole) delayed-release tablets, 100 
grams (g), was not withdrawn from sale for reasons of safety or 
effectiveness. The document incorrectly listed the dosage strength as 
100 g. The correct strength is 100 milligrams (mg). This notice 
corrects that error.

FOR FURTHER INFORMATION CONTACT: Awo Archampong-Gray, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6243, Silver Spring, MD 20993-0002, 301-
796-0110, [email protected].

SUPPLEMENTARY INFORMATION: In FR Doc. 2024-23811, published in the 
Federal Register of Wednesday, October 16, 2024 (89 FR 83504), 
appearing on pages 83504 and 83505, the following corrections are made:
    1. On page 83504, in the second column, the title of the document 
is corrected to read ``Determination That NOXAFIL (Posaconazole) 
Delayed-Release Tablets, 100 Milligrams, Was Not Withdrawn From Sale 
for Reasons of Safety or Effectiveness.''
    2. On page 83504, in the third column, in the SUMMARY, in the first 
paragraph, ``NOXAFIL (posaconazole) delayed-release tablets, 100 grams 
(g),'' is corrected to read ``NOXAFIL (posaconazole) delayed-release 
tablets, 100 milligrams (mg),''.
    3. On page 83505, in the first and second columns, all uses of 
``100 g'' are corrected to read ``100 mg''.

    Dated: November 7, 2024.
Kimberlee Trzeciak,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2024-27082 Filed 11-19-24; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.